WO2015100405A1 - Method of producing partially purified extracellular metabolite products from bacillus coagulans and biological applications thereof - Google Patents

Method of producing partially purified extracellular metabolite products from bacillus coagulans and biological applications thereof Download PDF

Info

Publication number
WO2015100405A1
WO2015100405A1 PCT/US2014/072331 US2014072331W WO2015100405A1 WO 2015100405 A1 WO2015100405 A1 WO 2015100405A1 US 2014072331 W US2014072331 W US 2014072331W WO 2015100405 A1 WO2015100405 A1 WO 2015100405A1
Authority
WO
WIPO (PCT)
Prior art keywords
bacillus coagulans
microbial
atcc
preparation
extracellular metabolite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/072331
Other languages
French (fr)
Inventor
Muhammed Majeed
Kalyanam Nagabhushanam
Sivakumar Arumugam
Furqan Ali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SG11201505628PA priority Critical patent/SG11201505628PA/en
Priority to AU2014369819A priority patent/AU2014369819B2/en
Priority to CN201480010615.0A priority patent/CN105189733B/en
Priority to EP14873856.0A priority patent/EP2989197B1/en
Priority to JP2016524399A priority patent/JP6126307B2/en
Priority to NZ711345A priority patent/NZ711345B/en
Priority to KR1020157023729A priority patent/KR101770902B1/en
Priority to CA2899511A priority patent/CA2899511C/en
Application filed by Individual filed Critical Individual
Priority to RU2015143406A priority patent/RU2617965C2/en
Publication of WO2015100405A1 publication Critical patent/WO2015100405A1/en
Priority to PH12015502025A priority patent/PH12015502025B1/en
Anticipated expiration legal-status Critical
Priority to AU2017228561A priority patent/AU2017228561B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
    • A01N31/08—Oxygen or sulfur directly attached to an aromatic ring system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/12—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group, wherein Cn means a carbon skeleton not containing a ring; Thio analogues thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/10—Animals; Substances produced thereby or obtained therefrom
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
    • A01N63/22—Bacillus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A01N65/08—Magnoliopsida [dicotyledons]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C12R2001/085—Bacillus cereus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/38—Pseudomonas
    • C12R2001/385—Pseudomonas aeruginosa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/44—Staphylococcus
    • C12R2001/445—Staphylococcus aureus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/44—Staphylococcus
    • C12R2001/45—Staphylococcus epidermidis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention in general relates to the anti-microbial effects of probiotic preparations. More specifically, the present invention relates to (1) a method for producing partially purified extracellular metabolite preparation from the probiotic bacterial strain Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050 and (2) the anti-microbial profile of said extracellular metabolite preparation against a panel of microbial pathogens, including synergistic anti-microbial effects of preparation when combined with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis.
  • the present invention pertains to further purification of extracellular components of cultures of probiotic Bacillus coagulans SB C37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) to obtain a concentrated extracellular metabolite preparation that exhibits enhanced anti-microbial effects when compared to the supernatant itself both alone and when combined with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis.
  • Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050.
  • Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050;
  • Bacillus coagulans SB C37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050;
  • Fig.l shows the process flowchart for a purification method to produce partially purified extracellular metabolite preparation from the probiotic bacterial strain Bacillus coagulans SBC37- 01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 3 1284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050.
  • Fig. 2 shows the representation of checkerboard broth micro-dilution method for synergistic anti-microbial studies.
  • Figs.3A-3B, 3C-3D, 3E-3F, 3G-3H, 3I-3J, 3K-3L, 3M-3N, 30-3P show respectively, the graphical representation of the effect of natural preservative blend and extracellular metaboliltes of B.
  • coagulans MTCC 5856 alone and in combination on the growth and viability of Pseudomonas aeruginosa ATCC 9027, Escherichia coli ATCC 25922, Salmonella abony NCIM 2257, Streptococcus mutans MTCC 1943, Propionibacterium acnes ATCC 11827, Staphylococcus aureus ATCC 29213, Staphlococcus epidermidis ATCC 14990 and Bacillus cereus ATCC 14579.
  • Figs. 4A, 4B, 4C, 4D and 4E show respectively, the graphical representations of the effect of natural preservative blend and extracellular metabolites of B, coagulans MTCC 5856 alone and in combination on the biofilm formation of Pseudomonas aeruginosa ATCC 9027, Escherichia coli ATCC 25922, Streptococcus mutans MTCC 1943 Staphylococcus aureus ATCC 29213 and Staphylococcus epidermidis ATCC 14990.
  • Figs.5A and 5B show respectively, the graphical representations of the effect of natural preservative blend and extracellular metabolites of B. coagulans MTCC 5856 on the growth/pH drop and the formation of water insoluble glucans of S. mutans MTCC 1943 biofilm in presence of 2% sucrose.
  • the present invention relates to a purification method for producing partially purified extracellular metabolite preparation from the probiotic bacterial strain Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050, said purification method comprising the steps of:
  • step 6 Incubating the mixture of step 5 at 0°C for 30 minutes followed by centrifuging at 7000-8000 rpm;
  • step 7 Discarding the pellet obtained in step 6 and collecting 60% acetone saturated supernatant ( ⁇ 200ml).
  • the present invention relates to a process of microbial control, said process comprising the step of bringing into contact effective concentrations of a partially purified extracellular metabolite preparation from probiotic bacterial strain Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 3 1284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050 and a target microbial cell.
  • the microbial cell may be one selected from the group comprising Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mutans, Propionibacterium acnes, Bacillus cereus and Salmonella abony.
  • the present invention relates to a process of microbial control, said process comprising the step of bringing into contact a microbial cell with effective concentrations of a preparation consisting essentially of partially purified extracellular metabolite preparation from probiotic bacterial strain Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050 and a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis.
  • the microbial cell may be one selected from the group comprising Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mutans, Propionibacterium acnes, Bacillus cereus and Salmonella abony.
  • the present invention also relates to a process of inhibiting microbial biofilm formation, said process comprising step of bringing into contact biofilm producing microbial cells and a preparation consisting essentially of partially purified extracellular metabolite preparation from probiotic bacterial strain Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050 alone or said preparation combined with a synergistic preservative blend comprising from about 61 % w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis.
  • the bacterial strains used in this study included Streptococcus mutans MTCC 1943, Staphylococcus aureus ATCC 29213, Staphylococcus epidermidis ATCC 14990, Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 9027, Salmonella abony NCIM 2257 and Bacillus cereus ATCC 14579.
  • the reference strains were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA), MTCC (IMTECH, Chandigarh, India) and NCIM (National Collection of Industrial Microorganisms, Pune, India). S. mutans and P.
  • acnes were maintained on brain-heart infusion agar (BHI; Difco Laboratories, Detroit, MI, USA) and reinforced clostridial agar (RCA; HiMedia, Mumbai, India) respectively.
  • BHI brain-heart infusion agar
  • RCA clostridial agar
  • S. aureus, S. epidermidis E. coll, P. aeruginosa, S. abony and B. cereus were maintained on trypticase soy agar (Difco Laboratories) at 37°C.
  • S. mutans and P. acnes were incubated anaerobically (80% N2, 10% 3 ⁇ 4 and 10% CO 2 ) at 37°C up to 48 h in anaerobic chamber (Coy Laboratory Products rnc, Michigan).
  • Bacillus coagulans SBC37-01 used in the study was characterized and deposited to Microbial Type Culture Collection, Chandigarh, India and the strain was assigned as Bacillus coagulans MTCC
  • each tube (or well) contains the same amount of the partially purified extracellular metabolite preparation from the probiotic bacterial strain Bacillus coagulans MTCC 5856 being diluted along the X-axis (rows) in which each tube (or well) contains the same amount of the preservative blend being diluted on the Y-axis (Fig 2).
  • each square in the checkerboard (which represents one tube/ well or plate) contained a unique combination of partially purified extracellular metabolite preparation from the probiotic bacterial strain Bacillus coagulans MTCC 5856 and preservative blend.
  • the concentration range of preservative blend in the present study was 2000 ⁇ ⁇ 1 to 31.25 ⁇ g/ml and lower in some cases, whereas the partially purified extracellular metabolite preparations from the probiotic bacterial strain Bacillus coagulans MTCC 5856 was tested in the range of 8 % (v/v) to 0.015 % (v/v).
  • This checkerboard technique can be performed with liquid or semisolid (agar) media.
  • BHI broth and RC broth were used for S. mutans and P. acnes respectively and plates were incubated anaerobically (80% N 2 , 10% H 2 and 10% C0 2 ) at 37°C up to 48 h in anaerobic chamber.
  • Mueller hinton broth (Difco) was used for S. aureus, S. epidermidis E. coli, P. aeruginosa, S. abony and B. cere s and plates were incubated at 37°C for 18 h.
  • the viable count and absorbance (OD 6 io) were taken at 0 (untreated control), and 24 h of incubation at 37°C. Viable count was expressed in Logio cfu/ml and absorbance was expressed in OD value at 610 nm.
  • the bacterial suspensions were prepared from the overnight- grown culture, and the turbidity of the suspension was adjusted to an optical density at 610 nm (A 6 io) of 0.7 (1 x 10 9 CFU/ml).
  • concentration range of preservative blend in the present study was 2000 ⁇ g/ml to 31.25 ⁇ g/ml and lower concentrations in some cases, whereas partially purified extracellular metabolite preparation from the strain Bacillus coagulans MTCC 5856 was tested in the range of 8 % (v/v) to 0.015 % (v/v). Forty microliters of fresh media broth was added to each well, followed by the addition of 60 ⁇ of the above-mentioned suspension to each well of the plate.
  • Biofilm formation was quantified by the addition of 200 ⁇ of 95% ethanol to the crystal violet- stained wells and recording the absorbance at 595 nm (A595). The percentage of biofilm inhibition was calculated using the equation (A595 of biofilm treated with test agent/A 5 95 of non-treated control) xlOO. Culture without test agent was used as the non-treated control.
  • mutans MTCC 1943 were gently washed with 10 ml of sterile water and resuspended in 10 ml of phosphate buffer (10 mM, pH 5.0) containing preservative blend and partially purified extracellular metabolite preparation from the strain Bacillus coagulans MTCC 5856 alone and in combination, followed by incubation at 37°C for 5 min. Chlorhexidine 0.12% (v/v) (Sigma Chemical Co., St Louis, MO) was used as internal reference in the study. The mixture was gently washed again with sterile saline (0.89% NaCl, w/v), followed by the resuspension of treated cells in 10 ml of BHI broth containing 2% sucrose (w/v).
  • the acid produced by the culture was measured by using a pH meter.
  • the fluid containing free cells of S. mutans MTCC was gently removed.
  • the water insoluble glucan was resuspended in 10 ml of 1 N NaOH solution and homogenized; the turbidity was measured at 610 nm.
  • Table 1 shows the fold reduction of human microbial pathogens when brought in contact with A. formulations containing just Partially Purified Extracellular Metabolites (PPEM) or Natural Preservative Blend (NPB); and B. formulations incorporating both Partially Purified Extracellular Metabolites (PPEM) and Natural Preservative Blend (NPB). It may be noted that the formulations incorporating both Partially Purified Extracellular Metabolites (PPEM) and Natural Preservative Blend (NPB) cause a significant eight fold decrease for pathogen Pseudomonas aeruginosa and four fold decrease for pathogen Escherichia coli.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Disclosed is a method for producing partially purified extracellular metabolite preparation from the probiotic bacterial strain Bacillus coagulans SBC-37 (Deposited in the Microbial Type Culture Collection and Gene Bank as strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050. Also disclosed is the anti-microbial profile of said extracellular metabolite preparation against a panel of microbial pathogens, including synergistic anti-microbial effects of preparation when combined with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis. The extracellular metabolite preparation alone or the combination of said extracellular metabolite preparation and preservative blend also inhibits microbial biofilm formation in a synergistic manner.

Description

METHOD OF PRODUCING PARTIALLY PURIFIED EXTRACELLULAR METABOLITE PRODUCTS FROM BACILLUS COAGULANS AND BIOLOGICAL APPLICATIONS THEREOF
CROSS-REFERENCE TO RELATED PATENT APPLICATION
This patent application is the non-provisional filing for provisional patent application US61920567 filed 24 December 2013 for the invention titled "METHOD OF PRODUCING PARTIALLY PURIFIED EXTRACELLULAR METABOLITE PRODUCTS FROM BACILLUS COAGULANS AND BIOLOGICAL APPLICATIONS THEREOF."
BACKGROUND OF THE INVENTION
[PARA 001] Field of the invention
[PARA 002] The invention in general relates to the anti-microbial effects of probiotic preparations. More specifically, the present invention relates to (1) a method for producing partially purified extracellular metabolite preparation from the probiotic bacterial strain Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050 and (2) the anti-microbial profile of said extracellular metabolite preparation against a panel of microbial pathogens, including synergistic anti-microbial effects of preparation when combined with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis. The extracellular metabolite preparation alone or the combination of said extracellular metabolite preparation and preservative blend is also shown to inhibit microbial biofilm formation in a synergistic manner.
[PARA 003] Description of prior art
[PARA 004] Extracellular products of Bacillus coagulans comprising a supernatant or filtrate of a culture Bacillus coagulans strain suitable for topical application to the skin or mucosal membranes of a mammal and thereby capable of being utilized to inhibit the growth of bacterium, yeast, fungi, virus, and combinations thereof is known in the art (US6905692, "Topical compositions containing probiotic Bacillus bacteria, spores, and extracellular products and uses thereof). The present invention pertains to further purification of extracellular components of cultures of probiotic Bacillus coagulans SB C37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) to obtain a concentrated extracellular metabolite preparation that exhibits enhanced anti-microbial effects when compared to the supernatant itself both alone and when combined with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis.
[PARA 005] It is the principle objective of the present invention to disclose
1) A method for producing partially purified extracellular metabolite preparation from the probiotic bacterial strain Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050. 2) The anti-microbial profile of said extracellular metabolite preparation against a panel of microbial pathogens, including synergistic anti-microbial effects of preparation when combined with a synergistic preservative blend comprising from about 61 % w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis.
3) The microbial biofilm inhibitory potential of said extracellular metabolite preparation alone or in combination with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis.
[PARA 006] The present invention fulfills the aforesaid objectives and provides further related advantages.
SUMMARY OF THE INVENTION [PARA 007] The present invention describes
(1) A method for producing partially purified extracellular metabolite preparation from the probiotic bacterial strain Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050;
(2) The anti-microbial profile of said extracellular metabolite preparation against a panel of microbial pathogens, including synergistic anti-microbial effects of preparation when combined with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis and
(3) The microbial biofilm inhibitory potential of said extracellular metabolite preparation alone or in combination with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis.
(4) The antimicrobial activity and anti-acidogenic effect against adherent S. mutans in water- insoluble glucans of said extracellular metabolite prepai'ation alone or in combination with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis.
[PARA 008] The present invention provides the following advantages.
1) Disclosure of a purification method for producing partially purified extracellular metabolite preparation from the probiotic bacterial strain Bacillus coagulans SB C37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050;
2) Disclosure of the anti-microbial profile of the partially purified against a panel of microbial pathogens, including synergistic anti-microbial effects of said partially purified extracellular preparation when combined with a synergistic preservative blend-comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis.
3) Disclosure of the microbial biofilm inhibitory potential of said extracellular metabolite preparation alone or in combination with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis.
4) Disclosure of the antimicrobial activity and anti-acido genie effect against adherent & mutans in water-insoluble glucans, of said extracellular metabolite preparation alone or in combination with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1%> w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis.
[PARA 009] Other features and advantages of the present invention will become apparent from the following more detailed description, taken in conjunction with the accompanying images, which illustrate, by way of example, the principle of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[PARA 0010] Fig.l shows the process flowchart for a purification method to produce partially purified extracellular metabolite preparation from the probiotic bacterial strain Bacillus coagulans SBC37- 01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 3 1284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050.
[PARA 0011] Fig. 2 shows the representation of checkerboard broth micro-dilution method for synergistic anti-microbial studies. [PARA 0012] Figs.3A-3B, 3C-3D, 3E-3F, 3G-3H, 3I-3J, 3K-3L, 3M-3N, 30-3P show respectively, the graphical representation of the effect of natural preservative blend and extracellular metaboliltes of B. coagulans MTCC 5856 alone and in combination on the growth and viability of Pseudomonas aeruginosa ATCC 9027, Escherichia coli ATCC 25922, Salmonella abony NCIM 2257, Streptococcus mutans MTCC 1943, Propionibacterium acnes ATCC 11827, Staphylococcus aureus ATCC 29213, Staphlococcus epidermidis ATCC 14990 and Bacillus cereus ATCC 14579.
[PARA 0013] Figs. 4A, 4B, 4C, 4D and 4E show respectively, the graphical representations of the effect of natural preservative blend and extracellular metabolites of B, coagulans MTCC 5856 alone and in combination on the biofilm formation of Pseudomonas aeruginosa ATCC 9027, Escherichia coli ATCC 25922, Streptococcus mutans MTCC 1943 Staphylococcus aureus ATCC 29213 and Staphylococcus epidermidis ATCC 14990.
[PARA 0014] Figs.5A and 5B show respectively, the graphical representations of the effect of natural preservative blend and extracellular metabolites of B. coagulans MTCC 5856 on the growth/pH drop and the formation of water insoluble glucans of S. mutans MTCC 1943 biofilm in presence of 2% sucrose.
DETAILED DESCRIPTION OF THE MOST PREFERRED EMBODIMENT
[PARA 0015] In the most preferred embodiment the present invention relates to a purification method for producing partially purified extracellular metabolite preparation from the probiotic bacterial strain Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050, said purification method comprising the steps of:
1. Inoculating a culture of Bacillus coagulans MTCC 5856 exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050 into 1.0 liter of Glucose Yeast Extract Acetate broth medium (HiMedia, Mumbai India) or MRS broth containing 0.5% tween 80 or Corn steep powder media; 2. Allowing the fermentation in the inoculated medium of step 1 to proceed for 24-48 h at 37°C with 120 rpm;
3. Centrifuging the fermentation broth of step 2 at 4000-7000 rpm;
4. Concentrating supernatants 10 fold by using rotary evaporator at 50°C of step 3.
5. Adding 150 ml of chilled acetone drop by drop to 100 ml of tenfold concentrated supernatants of step 4, followed by mixing;
6. Incubating the mixture of step 5 at 0°C for 30 minutes followed by centrifuging at 7000-8000 rpm;
7. Discarding the pellet obtained in step 6 and collecting 60% acetone saturated supernatant (~200ml).
8. Concentrating the acetone saturated supernatant in step 7 to 50 ml by rotary evaporator.
9. Adjusting the pH to 5.0 by using 4N HC1, filtered (0.22 micron; Millex, Millipore, India) and stored at -20°C till further use.
10. Freeze drying/spray drying/tray drying the supernatant of step 8.
[PARA 0016] In another most preferred embodiment, the present invention relates to a process of microbial control, said process comprising the step of bringing into contact effective concentrations of a partially purified extracellular metabolite preparation from probiotic bacterial strain Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 3 1284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050 and a target microbial cell. In more specific embodiments, the microbial cell may be one selected from the group comprising Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mutans, Propionibacterium acnes, Bacillus cereus and Salmonella abony.
[PARA 0017] In yet another most preferred embodiment, the present invention relates to a process of microbial control, said process comprising the step of bringing into contact a microbial cell with effective concentrations of a preparation consisting essentially of partially purified extracellular metabolite preparation from probiotic bacterial strain Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050 and a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis. In more specific embodiments, the microbial cell may be one selected from the group comprising Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mutans, Propionibacterium acnes, Bacillus cereus and Salmonella abony.
[PARA. 0018] In yet another most preferred embodiment, the present invention also relates to a process of inhibiting microbial biofilm formation, said process comprising step of bringing into contact biofilm producing microbial cells and a preparation consisting essentially of partially purified extracellular metabolite preparation from probiotic bacterial strain Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050 alone or said preparation combined with a synergistic preservative blend comprising from about 61 % w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis.
[PARA 0019] The following examples are presented herewith to illustrate the exemplary embodiments of the present invention.
[PARA 0020] EXAMPLE 1
[PARA 0021] Microorganisms and culture conditions
[PARA 0022] The bacterial strains used in this study included Streptococcus mutans MTCC 1943, Staphylococcus aureus ATCC 29213, Staphylococcus epidermidis ATCC 14990, Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 9027, Salmonella abony NCIM 2257 and Bacillus cereus ATCC 14579. The reference strains were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA), MTCC (IMTECH, Chandigarh, India) and NCIM (National Collection of Industrial Microorganisms, Pune, India). S. mutans and P. acnes were maintained on brain-heart infusion agar (BHI; Difco Laboratories, Detroit, MI, USA) and reinforced clostridial agar (RCA; HiMedia, Mumbai, India) respectively. S. aureus, S. epidermidis E. coll, P. aeruginosa, S. abony and B. cereus were maintained on trypticase soy agar (Difco Laboratories) at 37°C. S. mutans and P. acnes were incubated anaerobically (80% N2, 10% ¾ and 10% CO2) at 37°C up to 48 h in anaerobic chamber (Coy Laboratory Products rnc, Michigan). Bacillus coagulans SBC37-01 used in the study was characterized and deposited to Microbial Type Culture Collection, Chandigarh, India and the strain was assigned as Bacillus coagulans MTCC 5856.
[PARA 0023] Technique-The checkerboard method for synergy study
[PARA 0024] This is the most frequently used method to access the antimicrobial combinations in vitro. The term "checkerboard" refers to the pattern (of tubes or microtiter plate wells) formed by multiple dilutions of two drugs being tested (Eliopoulos GM, Moellering RC: Antimicrobial combinations. In Antibiotics in laboratory medicine. Edited by Lorian V. Baltimore, The Williams & Wilkins Co; 1991 :432- 492). In the present study, the checker board consisted of columns in which each tube (or well) contains the same amount of the partially purified extracellular metabolite preparation from the probiotic bacterial strain Bacillus coagulans MTCC 5856 being diluted along the X-axis (rows) in which each tube (or well) contains the same amount of the preservative blend being diluted on the Y-axis (Fig 2). As a result each square in the checkerboard (which represents one tube/ well or plate) contained a unique combination of partially purified extracellular metabolite preparation from the probiotic bacterial strain Bacillus coagulans MTCC 5856 and preservative blend. The concentration range of preservative blend in the present study was 2000 μ§ ηι1 to 31.25 μg/ml and lower in some cases, whereas the partially purified extracellular metabolite preparations from the probiotic bacterial strain Bacillus coagulans MTCC 5856 was tested in the range of 8 % (v/v) to 0.015 % (v/v). This checkerboard technique can be performed with liquid or semisolid (agar) media. BHI broth and RC broth were used for S. mutans and P. acnes respectively and plates were incubated anaerobically (80% N2, 10% H2 and 10% C02) at 37°C up to 48 h in anaerobic chamber. Mueller hinton broth (Difco) was used for S. aureus, S. epidermidis E. coli, P. aeruginosa, S. abony and B. cere s and plates were incubated at 37°C for 18 h.
[PARA 0025] Kill kinetics
[PARA 0026] Time— kill studies of the preservative blend and partially purified extracellular metabolite preparation from strain Bacillus coagulans MTCC 5856 were conducted against P. aeruginosa, E. coli, S. aureus S. epidermidis, S. mutans, P. acnes, B. cereus and Salmonella abony and evaluated using a time-kill curve method, as described previously (Eliopoulus GM, Moellering RCJ. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine, 4th edn. Baltimore: Williams & Willdns, 1996; 330-6.). Bacterial suspension in its logarithmic phase (1 x l O6 cfu/ml) was used as the inoculum. The preservative blend and partially purified extracellular metabolite preparation from strain Bacillus coagulans MTCC 5856 were tested alone and in combination at different concentrations, as determined in checkerboard assay. The cell population as cfu/ml was determined by a serial dilution method in triplicate on respective media and incubated in respective growth conditions. The viable count and absorbance (OD6io) were taken at 0 (untreated control), and 24 h of incubation at 37°C. Viable count was expressed in Logio cfu/ml and absorbance was expressed in OD value at 610 nm.
[PARA 0027] Biofilm susceptibility assays
[PARA 0028] The biofilm inhibitory effect of preservative blend and partially purified extracellular metabolite preparation from the strain Bacillus coagulans MTCC 5856 alone and in combination were examined against S. mutans, E. coli, S, aureus S. epidermidis and P. aerugenosa by the microdilution method (Wei et al. Journal of Antimicrob. Chemother. 2006. 57: 1100-1109.). This method was similar to the checkerboard method for planktonic cells. For S. mutans biofilm assay, BHI broth supplemented with 2% sucrose was used. In case of other organisms, TSB supplemented with 2% glucose was used in the study. The bacterial suspensions were prepared from the overnight- grown culture, and the turbidity of the suspension was adjusted to an optical density at 610 nm (A6io) of 0.7 (1 x 109 CFU/ml). The concentration range of preservative blend in the present study was 2000 μg/ml to 31.25 μg/ml and lower concentrations in some cases, whereas partially purified extracellular metabolite preparation from the strain Bacillus coagulans MTCC 5856 was tested in the range of 8 % (v/v) to 0.015 % (v/v). Forty microliters of fresh media broth was added to each well, followed by the addition of 60 μΐ of the above-mentioned suspension to each well of the plate. This resulted in the final inoculum of 6 x 107 CFU/ml in each well; After incubation at 37°C for 48 h, the culture supernatant from each well was decanted, and planktonic cells were removed by washing the wells with phosphate-buffered saline (PBS; pH 7.2). The biofilm was fixed with methanol for 15 min and then air dried at room temperature. The wells of the dried plate were stained with 0.1% (w/v) crystal violet (Sigma Chemical Co., St Louis, MO) for 10 min and rinsed thoroughly with water until the negative control wells appeared colorless. Biofilm formation was quantified by the addition of 200 μΐ of 95% ethanol to the crystal violet- stained wells and recording the absorbance at 595 nm (A595). The percentage of biofilm inhibition was calculated using the equation (A595 of biofilm treated with test agent/A595 of non-treated control) xlOO. Culture without test agent was used as the non-treated control.
[PARA 0029] Antimicrobial activity against adherent S. mutans in water-insoluble glucan
[PARA 0030] The formation of water-insoluble glucan by S. mutans MTCC 1943 was performed by a previously described method (Katsura et al., Antimicrob. Agents Chemother. 2001. 45:3009- 3013). Briefly, aliquots of 100 μΐ of culture of S. mutans MTCC 1943 (~ 1 χ 108 cells/ml) were inoculated into 10 ml of fresh BHI broth containing 2% sucrose (w/v) in the test tubes and incubated at 37°C for 24 h at an inclination of 30°. The fluid containing planktonic cells was gently removed. The water-insoluble glucan containing cells of S. mutans MTCC 1943 were gently washed with 10 ml of sterile water and resuspended in 10 ml of phosphate buffer (10 mM, pH 5.0) containing preservative blend and partially purified extracellular metabolite preparation from the strain Bacillus coagulans MTCC 5856 alone and in combination, followed by incubation at 37°C for 5 min. Chlorhexidine 0.12% (v/v) (Sigma Chemical Co., St Louis, MO) was used as internal reference in the study. The mixture was gently washed again with sterile saline (0.89% NaCl, w/v), followed by the resuspension of treated cells in 10 ml of BHI broth containing 2% sucrose (w/v). After incubation of cells at 37°C for 6, 12, 18, and 24 h, the acid produced by the culture was measured by using a pH meter. The fluid containing free cells of S. mutans MTCC was gently removed. The water insoluble glucan was resuspended in 10 ml of 1 N NaOH solution and homogenized; the turbidity was measured at 610 nm.
[PARA 0031] RESULTS
[PARA 0032] Table 1 shows the fold reduction of human microbial pathogens when brought in contact with A. formulations containing just Partially Purified Extracellular Metabolites (PPEM) or Natural Preservative Blend (NPB); and B. formulations incorporating both Partially Purified Extracellular Metabolites (PPEM) and Natural Preservative Blend (NPB). It may be noted that the formulations incorporating both Partially Purified Extracellular Metabolites (PPEM) and Natural Preservative Blend (NPB) cause a significant eight fold decrease for pathogen Pseudomonas aeruginosa and four fold decrease for pathogen Escherichia coli.
Table 1. Results of checkerboard testing of the natural preservative blend and partially purified extracellular metabolites of probiotic stain Bacillus coagulans MTCC 5856 against human pathogens
Figure imgf000014_0001
[PARA 0033] While the invention has been described with reference to a preferred embodiment it is to be clearly understood by those skilled in the art that the invention is not limited thereto. Rather, the scope of the invention is to be interpreted only in conjunction with the appended claims.

Claims

We claim,
1. A purification method for producing partially purified extracellular metabolite preparation from the probiotic bacterial strain Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NB C 3887 and Bacillus coagulans ATCC 7050, said purification method comprising the steps of:
1. Inoculating a culture of Bacillus coagulans MTCC 5856 exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050 into 1.0 liter of Glucose Yeast Extract Acetate broth medium or MRS broth containing 0.5% tween 80 or Corn steep powder media;
2. Allowing the fermentation in the inoculated medium of step 1 to proceed for 24-48 h at 37°C with 120 rpm;
3. Centrifuging the fermentation broth of step 2 at 4000-7000 rpm;
4. Concentrating supernatants 10 fold by using rotary evaporator at 50°C of step 3.
5. Adding 150 ml of chilled acetone drop by drop to 100 ml of tenfold concentrated supernatants of step 4, followed by mixing;
6. Incubating the mixture of step 5 at 0°C for 30 minutes followed by centrifuging at 7000-8000 rpm;
7. Discarding the pellet obtained in step 6 and collecting 60% acetone saturated supernatant (~200ml).
8. Concentrating the acetone saturated supernatant in step 7 to 50 ml by rotary evaporator.
9. Adjusting the pH to 5.0 by using 4N HC1, filtered (0.22 micron; Millex, Millipore, India) and stored at -20°C till further use.
10. Freeze drying/spray drying/tray drying the supernatant of step 8.
2. A process of microbial control, said process comprising the step of bringing into contact effective concentrations of a partially purified extracellular metabolite preparation from probiotic bacterial strain Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NB C 3887 and Bacillus coagulans ATCC 7050 and a target microbial cell.
3. The process of claim 2 wherein the microbial cell is one selected from the group comprising Pseudomonas aeruginosa, Escherichia co i, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mutans, Propionibacterium acnes, Bacillus cereus and Salmonella abony,
4. A process of microbial control, said process comprising the step of bringing into contact a microbial cell with effective concentrations of a preparation consisting essentially of partially purified extracellular metabolite preparation from probiotic bacterial strain Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050 and a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis.
5. The process of claim 4 wherein the microbial cell is one selected from the group comprising Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mutans, Propionibacterium acnes, Bacillus cereus and Salmonella abony.
6. A process of inhibiting microbial biofilm formation, said process comprising step of bringing into contact biofilm producing microbial cells and a preparation consisting essentially of partially purified extracellular metabolite preparation from probiotic bacterial strain Bacillus coagu!ansSBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050 alone or said preparation combined with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis.
7 The process of claim 6 wherein the biofilm producing microbial cell is one selected from the group comprising Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mutans.
8. A process of preventing pH drop and further accumulation of biofilm of Streptococcus mutans in presence of sucrose, said process comprising step of bringing into contact biofilm/plaque producing Streptococcus mutans and a preparation consisting essentially of partially purified extracellular metabolite preparation from probiotic bacterial strain Bacillus coagulans SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050 alone or said preparation combined with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis.
PCT/US2014/072331 2013-12-24 2014-12-24 Method of producing partially purified extracellular metabolite products from bacillus coagulans and biological applications thereof Ceased WO2015100405A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
KR1020157023729A KR101770902B1 (en) 2013-12-24 2014-12-24 Method of producing partially purified extracellular metabolite products from bacillus coagulans and biological applications thereof
CN201480010615.0A CN105189733B (en) 2013-12-24 2014-12-24 Method for producing partially purified extracellular metabolites from bacillus coagulans and biological applications thereof
EP14873856.0A EP2989197B1 (en) 2013-12-24 2014-12-24 Method of producing partially purified extracellular metabolite products from bacillus coagulans and biological applications thereof
JP2016524399A JP6126307B2 (en) 2013-12-24 2014-12-24 Methods for producing partially purified extracellular metabolites from Bacillus coagulans and their biological uses
NZ711345A NZ711345B (en) 2013-12-24 2014-12-24 Method of producing partially purified extracellular metabolite products from bacillus coagulans and biological applications thereof
SG11201505628PA SG11201505628PA (en) 2013-12-24 2014-12-24 Method of producing partially purified extracellular metabolite products from bacillus coagulans and biological applications thereof
AU2014369819A AU2014369819B2 (en) 2013-12-24 2014-12-24 Method of producing partially purified extracellular metabolite products from bacillus coagulans and biological applications thereof
CA2899511A CA2899511C (en) 2013-12-24 2014-12-24 Method of producing partially purified extracellular metabolite products from bacillus coagulans and biological applications thereof
RU2015143406A RU2617965C2 (en) 2013-12-24 2014-12-24 Method of preparation of extracellular metabolites of bacillus coagulans and its biological applications
PH12015502025A PH12015502025B1 (en) 2013-12-24 2015-09-09 Method of producing partially purified extracellular metabolite products from bacillus coagulans and biological applications thereof
AU2017228561A AU2017228561B2 (en) 2013-12-24 2017-09-12 Method of producing partially purified extracellular metabolite products from bacillus coagulans and biological applications thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361920567P 2013-12-24 2013-12-24
US61/920,567 2013-12-24

Publications (1)

Publication Number Publication Date
WO2015100405A1 true WO2015100405A1 (en) 2015-07-02

Family

ID=53398649

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/072331 Ceased WO2015100405A1 (en) 2013-12-24 2014-12-24 Method of producing partially purified extracellular metabolite products from bacillus coagulans and biological applications thereof

Country Status (12)

Country Link
US (4) US9596861B2 (en)
EP (1) EP2989197B1 (en)
JP (1) JP6126307B2 (en)
KR (1) KR101770902B1 (en)
CN (1) CN105189733B (en)
AU (2) AU2014369819B2 (en)
CA (1) CA2899511C (en)
MY (1) MY181102A (en)
PH (1) PH12015502025B1 (en)
RU (1) RU2617965C2 (en)
SG (1) SG11201505628PA (en)
WO (1) WO2015100405A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206033A (en) * 2016-01-07 2017-09-26 萨米莱布斯有限公司 Therapeutic management of diarrhea-predominant irritable bowel syndrome using Bacillus coagulans SBC37‑01, MTCC 5856
CN107937447A (en) * 2017-11-10 2018-04-20 嘉兴欣贝莱生物科技有限公司 A method for biosynthesizing magnolol
EP3185877A4 (en) * 2014-08-29 2018-04-25 Muhammed Majeed Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof
WO2018226554A1 (en) 2017-06-06 2018-12-13 Muhammed Majeed Skin care applications of extracellular metabolites from bacillus coagulans

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015227075A1 (en) 2014-03-06 2016-09-22 Ohio State Innovation Foundation Probiotic formulations and methods for use
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
NZ748553A (en) * 2016-06-30 2021-07-30 Sami Labs Ltd Bacillus coagulans mtcc 5856 for the management of major depressive disorder
WO2018183355A1 (en) * 2017-03-27 2018-10-04 Research Institute At Nationwide Children's Hospital Prebiotic formulations
CA3063991A1 (en) * 2017-05-26 2018-11-29 Sami Labs Limited Beverage compositions containing bacillus coagulans mtcc 5856
JP7150753B2 (en) * 2017-06-06 2022-10-11 サミ－サビンサ グループ リミテッド Hair care compositions containing extracellular metabolite preparations derived from Bacillus coagulans
AU2018282252B2 (en) * 2017-06-06 2021-07-15 Sami Labs Limited Anti-aging potential of extracellular metabolite isolated from Bacillus coagulans MTCC 5856
WO2018226271A1 (en) * 2017-06-09 2018-12-13 Muhammed Majeed Hypolipidemic effects of bacillus coagulans
DK3662053T3 (en) * 2017-07-31 2025-01-06 Univ Princeton CRYPTIC METABOLITES AND METHOD FOR ACTIVATING SILENT BIOSYNTHETIC REGENERATION IN VARIOUS MICROORGANISMS
BR112020004050A2 (en) * 2017-08-31 2020-09-01 Sami Labs Limited anti-pollution compositions containing bacillus coagulans
EP3684900B1 (en) * 2017-09-21 2024-11-06 Sami-Sabinsa Group Limited Alcoholic beverage composition containing bacillus coagulans
WO2019112990A1 (en) * 2017-12-04 2019-06-13 Muhammed Majeed Compositions for microbial anti-adhesion
CA3155357A1 (en) * 2018-04-30 2019-11-07 Sami Labs Limited Modulation of immune function by bacillus coagulans
US12569524B2 (en) 2018-10-22 2026-03-10 Research Institute At Nationwide Children's Hospital Compositions and methods for preventing and treating antibiotic induced pathologies using probiotics in the biofilm state
BR112021013484A2 (en) * 2019-01-10 2021-09-14 Evonik Operations Gmbh DRY FERMENTATION BROTH OF MICRO-ORGANISMS, COMPOSITION AND METHODS
JP7469332B2 (en) * 2019-05-13 2024-04-16 サミ－サビンサ グループ リミテッド Fructophilic lactic acid producing bacteria
WO2020247536A1 (en) 2019-06-03 2020-12-10 Research Institute At Nationwide Children's Hospital Prebiotic formulations for prevention of sepsis and necroenterocolitis induced neurodevelopmental deficiencies
CN114958676B (en) * 2022-06-15 2024-02-20 扬州大学 An antibacterial agent based on Bacillus fermentation products and its preparation method and application
CN116064330B (en) * 2023-01-10 2024-05-03 北京工商大学 Bacillus coagulans and application thereof
CN117305160A (en) * 2023-09-19 2023-12-29 无锡爱科派生物科技有限公司 Compound bacillus coagulans microbial inoculum and preparation method and application thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047374A1 (en) 1997-04-18 1998-10-29 Ganeden Biotech, Inc. Topical use of probiotic bacillus spores to prevent or control microbial infections
WO1998054982A1 (en) 1997-06-03 1998-12-10 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with sids
WO2000010582A2 (en) 1998-08-24 2000-03-02 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
WO2000061201A1 (en) 1999-04-14 2000-10-19 Ganeden Biotech, Inc. Methods for inhibiting microbial infections associated with sanitary products
WO2001013927A2 (en) 1999-08-26 2001-03-01 Ganeden Biotech, Inc. Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof
WO2001013956A2 (en) 1999-08-26 2001-03-01 Ganeden Biotech, Inc. Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications
WO2001034168A1 (en) 1999-11-08 2001-05-17 Ganeden Biotech, Inc. Inhibition of pathogens by bacillus coagulans strains
US7507402B1 (en) 1997-04-18 2009-03-24 Ganeden Biotech, Inc. Topical use of probiotic Bacillus spores to prevent or control microbial infections
WO2009099562A2 (en) 2008-01-30 2009-08-13 Ganeden Biotech, Inc. Compositions and methods for cleaning surfaces
US20100120911A1 (en) 2008-05-02 2010-05-13 Muhammed Majeed Preservative system for cosmetic formulations
WO2012079973A1 (en) * 2010-12-17 2012-06-21 Unilever Nv Food product comprising probiotic bacterial spores
US20120251512A1 (en) * 2011-03-31 2012-10-04 Ganeden Biotech, Inc. Probiotic Sports Nutrition Compositions
US20140094517A1 (en) 2012-10-01 2014-04-03 Muhammed Majeed Preservative system for cosmetic formulations- compositions and methods thereof
US20140308733A1 (en) * 2011-09-08 2014-10-16 Calpis Co., Ltd. Method for inducing germination of spore forming bacterium

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2057806C1 (en) * 1994-05-17 1996-04-10 Товарищество с ограниченной ответственностью "Сибэнзим" Strain of bacterium bacillus coagulans - a producer of restriction endonuclease recognizing and splitting the nucleotide sequence 5′-gatnnnn-atc-3′
US6413501B2 (en) * 1997-10-17 2002-07-02 Novozymes A/S Plaque-inhibiting oral compositions
EE04529B1 (en) * 2001-03-16 2005-08-15 Tartu �likool Thermophilic microorganism strain Bacillus coagulans SIM-7 DSM 14043 and method for the production of L (+) - lactate from fermentable sugars and mixtures thereof by said microorganism strain
US20040197277A1 (en) * 2001-08-24 2004-10-07 The Procter & Gamble Company Chewable compositions with probiotic agents
CN101503708B (en) * 2009-03-05 2012-04-11 天津科技大学 A kind of cultivation and fermentation method of bacillus coagulans antifungal active substance
US20110110894A1 (en) * 2009-11-10 2011-05-12 Novozymes Biologicals, Inc. Methods, compositions and systems for controlling fouling of a membrane

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507402B1 (en) 1997-04-18 2009-03-24 Ganeden Biotech, Inc. Topical use of probiotic Bacillus spores to prevent or control microbial infections
WO1998047374A1 (en) 1997-04-18 1998-10-29 Ganeden Biotech, Inc. Topical use of probiotic bacillus spores to prevent or control microbial infections
US6905692B2 (en) 1997-04-18 2005-06-14 Ganeden Biotech, Inc. Topical compositions containing probiotic bacillus bacteria, spores, and extracellular products and uses thereof
WO1998054982A1 (en) 1997-06-03 1998-12-10 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with sids
WO2000010582A2 (en) 1998-08-24 2000-03-02 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
WO2000061201A1 (en) 1999-04-14 2000-10-19 Ganeden Biotech, Inc. Methods for inhibiting microbial infections associated with sanitary products
WO2001013927A2 (en) 1999-08-26 2001-03-01 Ganeden Biotech, Inc. Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof
WO2001013956A2 (en) 1999-08-26 2001-03-01 Ganeden Biotech, Inc. Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications
WO2001034168A1 (en) 1999-11-08 2001-05-17 Ganeden Biotech, Inc. Inhibition of pathogens by bacillus coagulans strains
WO2009099562A2 (en) 2008-01-30 2009-08-13 Ganeden Biotech, Inc. Compositions and methods for cleaning surfaces
US20100120911A1 (en) 2008-05-02 2010-05-13 Muhammed Majeed Preservative system for cosmetic formulations
WO2012079973A1 (en) * 2010-12-17 2012-06-21 Unilever Nv Food product comprising probiotic bacterial spores
US20120251512A1 (en) * 2011-03-31 2012-10-04 Ganeden Biotech, Inc. Probiotic Sports Nutrition Compositions
US20140308733A1 (en) * 2011-09-08 2014-10-16 Calpis Co., Ltd. Method for inducing germination of spore forming bacterium
US20140094517A1 (en) 2012-10-01 2014-04-03 Muhammed Majeed Preservative system for cosmetic formulations- compositions and methods thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"LACTOSPORE", 31 August 2007 (2007-08-31), pages 1 - 44, XP055240367, Retrieved from the Internet <URL:http://www.sabinsa.com/products/probiotics-synbiotics/lactospore/lactospore-booklet.pdf> [retrieved on 20150309] *
ELIOPOULOS GM; MOELLERING RC: "Antibiotics in laboratory medicine", 1991, THE WILLIAMS & WILKINS CO, article "Antimicrobial combinations", pages: 432 - 492
ELIOPOULUS GM; MOELLERING RCJ: "Antibiotics in Laboratory Medicine", 1996, WILLIAMS & WILKINS, article "Antimicrobial combinations", pages: 330 - 6
KATSURA ET AL., ANTIMICROB. AGENTS CHEMOTHER, vol. 45, 2001, pages 3009 - 3013
MAJEED ET AL.: "Bacillus coagulans: Probiotic of choice", NUTRACOS PERBIOTICS/PROBIOTICS, March 2012 (2012-03-01), pages 19 - 21, XP055240361 *
MAJEED, M.; KAMAREI, R.: "PREBIOTICS/PROBIOTICS ''Bacillus coagulans: Probiotic of choice", NUTRACOS, 2012
RIAZI ET AL.: "Characterization of lactosporin, a novel antimicrobial protein produced by Bacillus coagulans ATCC 7050", JOURNAL OF APPLIED MICROBIOLOG, vol. 106, 2009, pages 1370 - 1377, XP055240375 *
RIAZI, S ET AL., JOURNAL OF APPLIED MICROBIOLOGY, vol. 106, 2009, pages 1370 - 1377
See also references of EP2989197A4
WEI ET AL., JOURNAL OF ANTIMICROB. CHEMOTHER, vol. 57, 2006, pages 1100 - 1109

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3185877A4 (en) * 2014-08-29 2018-04-25 Muhammed Majeed Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof
CN107206033A (en) * 2016-01-07 2017-09-26 萨米莱布斯有限公司 Therapeutic management of diarrhea-predominant irritable bowel syndrome using Bacillus coagulans SBC37‑01, MTCC 5856
CN107206033B (en) * 2016-01-07 2021-04-27 萨米莱布斯有限公司 Therapeutic management of diarrhea-predominant irritable bowel syndrome using Bacillus coagulans SBC37-01, MTCC 5856
WO2018226554A1 (en) 2017-06-06 2018-12-13 Muhammed Majeed Skin care applications of extracellular metabolites from bacillus coagulans
CN107937447A (en) * 2017-11-10 2018-04-20 嘉兴欣贝莱生物科技有限公司 A method for biosynthesizing magnolol

Also Published As

Publication number Publication date
JP2016523104A (en) 2016-08-08
SG11201505628PA (en) 2015-08-28
RU2015143406A (en) 2017-04-20
AU2014369819A1 (en) 2015-09-10
RU2617965C2 (en) 2017-04-28
US20160324162A1 (en) 2016-11-10
MY181102A (en) 2020-12-17
NZ711345A (en) 2017-07-28
KR101770902B1 (en) 2017-08-24
CA2899511A1 (en) 2015-07-02
CA2899511C (en) 2018-11-27
US9681666B2 (en) 2017-06-20
CN105189733A (en) 2015-12-23
KR20150113979A (en) 2015-10-08
AU2017228561B2 (en) 2018-12-13
PH12015502025A1 (en) 2016-01-18
AU2014369819B2 (en) 2017-09-28
US9635862B2 (en) 2017-05-02
PH12015502025B1 (en) 2019-08-23
US20150173374A1 (en) 2015-06-25
AU2017228561A1 (en) 2017-10-05
EP2989197A4 (en) 2016-04-06
US9596861B2 (en) 2017-03-21
US20160324163A1 (en) 2016-11-10
JP6126307B2 (en) 2017-05-10
CN105189733B (en) 2018-09-18
US9681665B2 (en) 2017-06-20
US20160324161A1 (en) 2016-11-10
EP2989197B1 (en) 2018-08-29
EP2989197A1 (en) 2016-03-02

Similar Documents

Publication Publication Date Title
AU2017228561B2 (en) Method of producing partially purified extracellular metabolite products from bacillus coagulans and biological applications thereof
Sharaf et al. Evaluation and characterization of some protective culture metabolites in free and nano-chitosan-loaded forms against common contaminants of Egyptian cheese
Furneri et al. In vitro antimycoplasmal activity of oleuropein
Oonmetta-aree et al. Antimicrobial properties and action of galangal (Alpinia galanga Linn.) on Staphylococcus aureus
Erturk et al. Antibacterial and antifungal effects of some marine algae
Bokaeian et al. The antibacterial activity of silver nanoparticles produced in the plant Sesamum indicum seed extract: a green method against multi-drug resistant Escherichia coli
Hashim The synergistic effect of biosynthesized gold nanoparticles with antibiotic against clinical isolates
EP1481666B1 (en) A composition for re-establishment of the vaginal ecosystem
Amalia et al. Antimicrobial activity of chitosan nanoparticles loaded with 0.7% tetracycline against porphyromonas gingivalis
JP6912051B2 (en) Composition
Missier et al. Antibacterial Properties of Lemon Juice–Mediated Zinc Oxide Nanoparticle and Titanium Dioxide Nanoparticle
Guirguis Enhancing the antibacterial effect of bacteriocin from Lactococcus lactis subsp. Lactis using chitosan nanoparticles
NZ711345B (en) Method of producing partially purified extracellular metabolite products from bacillus coagulans and biological applications thereof
Riaz et al. A Thematic Review on Potential Antimicrobial Potential Applications of Bacteriocins from Lactic Acid Bacteria
Hashem et al. Combinatorial effect of probiotics and some medicinal oils on pathogenic bacteria
Mamora et al. Antimicrobial Activity of Silver Nanoparticles Biosynthesized by Metabolites of Lactic Acid Bacteria Isolated from Fermented Cyperus esculentus Milk
Kadhim et al. The Synergistic Effect between Antibiotics and Biosynthesized ZnO Nanoparticles.
Maina et al. Antimicrobial activity and characteristics of bacteriocin producing Bacillus subtilis against mastitis pathogens
Alfassam et al. Household Essential Oils as Antimicrobial Agents for Health and Skin care
Ekezie et al. Antimicrobial Efficacy of Zinc Nanoparticles Synthesized from Bitter Gourd Extract
Ibrahim et al. Benha Veterinary Medical Journal
Nighat et al. ORGANIC AND BIOCHEMISTRY
Abd El-Mongy et al. Synergistic effect of some medicinal plants oils incorporated with silver Nanoparticles against different Gram negative bacteria
El-Mongy et al. Synergistic effect of some medicinal plant oils incorporated with silver nanoparticles against different Gram-negative bacteria.
Dulger et al. Antimicrobial activity of Bacopa caroliniana

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480010615.0

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2899511

Country of ref document: CA

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14873856

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20157023729

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12015502025

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2014369819

Country of ref document: AU

Date of ref document: 20141224

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016524399

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IDP00201506134

Country of ref document: ID

WWE Wipo information: entry into national phase

Ref document number: 2014873856

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015143406

Country of ref document: RU

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE